BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21586752)

  • 1. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
    Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
    Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.
    Wang J; Liu Y; Tan LX; Lo JC; Du J; Ryu MJ; Ranheim EA; Zhang J
    Cell Cycle; 2011 Sep; 10(17):2836-9. PubMed ID: 21857161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.
    Wang J; Liu Y; Li Z; Du J; Ryu MJ; Taylor PR; Fleming MD; Young KH; Pitot H; Zhang J
    Blood; 2010 Dec; 116(26):5991-6002. PubMed ID: 20921338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.
    Li Q; Bohin N; Wen T; Ng V; Magee J; Chen SC; Shannon K; Morrison SJ
    Nature; 2013 Dec; 504(7478):143-147. PubMed ID: 24284627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
    Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
    Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
    Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
    PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
    Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
    J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
    Zambetti NA; Firestone AJ; Remsberg JR; Huang BJ; Wong JC; Long AM; Predovic M; Suciu RM; Inguva A; Kogan SC; Haigis KM; Cravatt BF; Shannon K
    Blood; 2020 May; 135(20):1772-1782. PubMed ID: 32219446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic N-Ras Mitigates Oxidative Stress-Induced Apoptosis of Hematopoietic Stem Cells.
    Ney GM; Yang KB; Ng V; Liu L; Zhao M; Kuk W; Alaka L; Sampang L; Ross A; Jones MA; Jin X; McKay LM; Evarts H; Li Q
    Cancer Res; 2021 Mar; 81(5):1240-1251. PubMed ID: 33441311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
    Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
    Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
    Parikh C; Subrahmanyam R; Ren R
    Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
    Melo-Cardenas J; Xu Y; Wei J; Tan C; Kong S; Gao B; Montauti E; Kirsammer G; Licht JD; Yu J; Ji P; Crispino JD; Fang D
    Blood; 2018 Jul; 132(4):423-434. PubMed ID: 29844011
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
    Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
    J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.